阅读说明：本技术 一个具有逆转肿瘤多药耐药活性的新骨架环脂肽化合物、其制备方法及用途 (Novel skeleton cyclic lipopeptide compound with tumor multidrug resistance reversing activity, preparation method and application thereof ) 是由 岳建民 楼丽广 刘翠萍 谢成英 纪开龙 赵金鑫 于 2019-03-12 设计创作，主要内容包括：本发明涉及从楝科<Image he="69" wi="51" file="DDA0001992691840000011.GIF" imgContent="drawing" imgFormat="GIF" orientation="portrait" inline="no"></Image>木属植物香港<Image he="65" wi="52" file="DDA0001992691840000012.GIF" imgContent="drawing" imgFormat="GIF" orientation="portrait" inline="no"></Image>木中提取分离得到的一个能够逆转肿瘤细胞耐药活性的新骨架环脂肽化合物。该化合物结构新颖,能显著提高化疗药物对多药耐药肿瘤细胞的增殖抑制活性。本发明涉及该化合物的提取分离制备方法,同时还涉及其用于制备治疗某些多药耐药肿瘤药物的用途。(The present invention relates to the family Meliaceae Hong Kong of woody plant A new skeleton cyclic lipopeptide compound capable of reversing the drug resistance activity of tumor cells is extracted and separated from wood. The compound has novel structure, and can remarkably improve the proliferation inhibition activity of the chemotherapeutic drug on multidrug resistant tumor cells. The invention relates to a method for extracting, separating and preparing the compound, and also relates to the application of the compound in preparing a medicine for treating certain diseasesThe application of the multi-drug resistant tumor drugs.)

1. A cyclic lipopeptide compound H-1, the structure of which is shown below:

2. a process for the preparation of cyclic lipopeptide compound H-1 according to claim 1 comprising the steps of:

a) will hong KongExtracting bark powder of wood with ethanol, steaming to remove ethanolConcentrating with alcohol to obtain extract;

b) extracting and distributing the extract by using ethyl acetate and water, evaporating an organic solvent to dryness to obtain a crude extract, performing gradient elution on the crude extract on a D101 macroporous adsorption resin column by using 30 percent, 50 percent, 80 percent and 90 percent of ethanol aqueous solution in volume fraction in sequence, and collecting an elution component F3 of the 80 percent of ethanol aqueous solution;

c) and purifying and separating the component F3 by MCI column chromatography, silica gel column chromatography and reversed-phase RP-18 column chromatography in sequence, and obtaining the cyclic lipopeptide compound H-1 by precipitation and purification.

3. The method of claim 2, wherein: the ethanol in the step a) is ethanol with the volume fraction of 95%, and the extraction temperature is normal temperature.

4. The method of claim 2, wherein: the eluent of the MCI column chromatography in the step c) is a methanol/water system, the eluent of the silica gel column chromatography is a petroleum ether/acetone system, and the eluent of the reversed-phase RP-18 column chromatography is a methanol/water system.

5. The method of claim 2, comprising the steps of:

a) dried hong KongExtracting cortex Cinnamomi Japonici powder with 95% ethanol at room temperature for 3 times, evaporating to remove ethanol, and concentrating to obtain extract;

b) extracting and distributing the extract by using ethyl acetate and water, evaporating an organic solvent to dryness to obtain a crude extract, and sequentially carrying out gradient elution on the crude extract on a D101 macroporous adsorption resin column by using ethanol water solutions with volume fractions of 30%, 50%, 80% and 90% to respectively and correspondingly obtain four elution components F1, F2, F3 and F4;

c) and purifying and separating the eluted component F3 by MCI column chromatography, silica gel column chromatography and reversed-phase RP-18 column chromatography in sequence, and finally obtaining the cyclic lipopeptide compound H-1 by precipitation and purification.

6. A pharmaceutical composition comprising the cyclic lipopeptide compound H-1 of claim 1.

7. Use of the cyclic lipopeptide compound H-1 according to claim 1 or the pharmaceutical composition according to claim 6 in the preparation of a medicament for the treatment of multidrug resistant tumors.

8. Use according to claim 7, characterized in that: the medicine for treating the multidrug resistant tumor is used for improving the tumor inhibition activity when being used together with a chemotherapy medicine.

9. Use according to claim 8, characterized in that: the chemotherapeutic drug comprises one or more of vincristine, paclitaxel and adriamycin.

Technical Field

The invention belongs to the technical field of medicine application, relates to an anti-tumor medical application of a novel skeleton cyclic lipopeptide compound with tumor multidrug resistance reversing activity, and more particularly relates to a new skeleton cyclic lipopeptide compound with tumor multidrug resistance reversing activity from Meliaceae

Hong Kong of woody plantA new skeleton cyclic lipopeptide compound extracted and separated from wood, a preparation method of the component, a tumor drug resistance reversing effect and an application prospect.

Background

Malignant tumor is a serious disease seriously threatening the life health and social development of human beings, and is a main reason of death of residents in China. In recent years, despite the tremendous advances we have made in the prevention, detection and treatment of malignant cancers; the problem of multidrug resistance in tumors remains a major obstacle to complete cure of a variety of cancers, including leukemia, breast cancer, ovarian cancer, lung cancer, and digestive tract cancer.

Multidrug resistance (MDR) of tumors means that once a tumor cell is resistant to a certain chemotherapeutic drug, it will generate broad-spectrum cross-resistance to a series of antineoplastic drugs with unrelated structures and functions, resulting in that the chemotherapeutic drug cannot effectively kill the cancer cell. The mechanism for generating the MDR is very complex, is related to various factors, and is not completely resolved at present, and the main reasons are as follows: (1) transporter-mediated drug efflux. These transporters include the ABC (ATP-binding cassette) transporter superfamily, such as P-glycoprotein (P-glycoprotein), MDR-related protein-1 (multi-drug resistance association protein-1, MRP1/ABCC1), and breast cancer resistance protein (ABCG 2), etc. These transporters can "pump" the anti-cancer drug out of the cell as a substrate, reducing the intracellular drug concentration, resulting in the development of drug resistance in the cell. (2) Abnormal drug-induced intracellular enzyme expression. For example, the expression of topoisomerase (Topo II) is reduced, the activity is reduced or gene mutation is carried out, so that the cell can generate drug resistance to Topo II targeted antitumor drugs; over-expression of glutathione-S-transferase (GST) accelerates excretion, reduces tumor killing, and generates drug resistance. (3) Drug-induced DNA damage repairs dysfunctions. The mismatch repair function of DNA is lost, the initiation of apoptosis signal path is damaged, and the resistance to the anticancer medicine acting on DNA is obtained.

Overexpression of P-gp is one of the leading causes of tumor MDR and is the most widely and deeply studied mechanism of resistance. At present, the reversal of tumor drug resistance is mainly a chemical reversal agent developed aiming at P-gp, and because of large toxic and side effects, the clinical application is limited, so that the search for a low-toxicity and high-efficiency drug resistance reversal agent becomes the key point of the research in the field of tumor chemotherapy drugs. Chinese medicine has a long history and rich experience in clinical use, and with the continuous development of modern medicine technology, the application and research of Chinese medicine develops new vitality. The discovery of novel chemical components from Chinese medicine for the treatment of tumor MDR has become an important direction for MDR reversal agent research in recent years. Meanwhile, the natural product has the characteristic of structural skeleton diversity, so that the natural product becomes one of important sources of a medicine lead structure.

Meliaceae family

Woody plants are about 75 species throughout the world, distributed in india, central and south peninsula, malaysia, indonesia to australia and new zealand. The 15 varieties of the 1 variety produced in China are distributed in Taiwan, Guangdong, Guangxi, Hainan, Yunnan and other provinces. Hong KongWood (Dysoxylum hongkongense) isOne species of wood, mainly produced in Guangdong, Guangxi, Hainan, hong Kong and YunnanEtc.; growing in dense forest or sparse forest of low-to medium-altitude mountainous regions; the leaves and bark of the plant are commonly used for treating malaria.

To date, in hong KongOnly a few chemical components are reported in the study of wood, mainly diterpene, diterpene derivative and triterpene components, and the structure, preparation method and application of the compounds are not reported in the invention. The invention relates to an unprecedented new framework compound, in an antitumor biological experiment, the compound is found to be capable of obviously enhancing the proliferation inhibition effect of common clinical chemotherapeutic drugs such as vincristine, paclitaxel and adriamycin on drug-resistant tumor cells KBV200, MDR/ADR and K562/ADR for the first time, and the compound has no obvious proliferation inhibition activity on the tumor cells when used alone, so that the conclusion that the compound can have the treatment effect on various multi-drug-resistant tumors is inferred, and the compound has huge potential application in the field of pharmacy.

Disclosure of the invention

The present invention relates to a method for screening a large number of plant extracts and natural monomer compounds from a Meliaceae familyHong Kong of woody plantSeparating to obtain a new skeleton cyclic lipopeptide compound.

One of the technical problems to be solved by the present invention is to provide a cyclic lipopeptide compound H-1, which has the following structure:

the compound is structurally characterized by being a novel skeleton compound with a 17-membered macrocyclic structure, wherein the novel skeleton compound is composed of a fatty acid chain with 19 carbons and 1L-type valine.

The second technical problem to be solved by the invention is to provide a preparation method of the cyclic lipopeptide compound H-1, which comprises the following steps:

a) will hong Kong

Extracting cortex Cinnamomi Japonici powder with ethanol, evaporating to remove ethanol, and concentrating to obtain extract;

b) distributing the extract with ethyl acetate and water, evaporating the organic solvent to dryness to obtain a crude extract, performing gradient elution on the crude extract on a D101 macroporous adsorption resin column by using 30 percent, 50 percent, 80 percent and 90 percent ethanol aqueous solution in sequence, and collecting an elution component F3 of the 80 percent ethanol aqueous solution;

c) and sequentially carrying out MCI column chromatography, silica gel column chromatography and reversed-phase RP-18 column chromatography on the eluted component F3 for purification and separation, and carrying out precipitation purification to obtain the cyclic lipopeptide compound H-1.

Preferably, the ethanol in step a) is 95% ethanol by volume fraction, the extraction temperature is preferably normal temperature, the extraction time is preferably 21 days, and the extraction time is 7 days for three times.

Preferably, the eluent of the MCI column chromatography in the step c) is a methanol/water system, the eluent of the silica gel column chromatography is a petroleum ether/acetone system, and the eluent of the reversed-phase RP-18 column chromatography is a methanol/water system.

Further preferably, in the step c), the MCI column chromatography is performed with gradient elution using eluents with methanol/water volume ratio of 1/1, 7/3 and 9/1 in sequence, and the elution component with methanol/water volume ratio of 7/3 is collected for silica gel column chromatography; gradient elution is carried out on the silica gel column chromatography by using eluents with petroleum ether/acetone volume ratios of 50/1, 20/1, 10/1, 2/1, 1/1 and 1/3 in sequence, and reversed-phase RP-18 column chromatography is carried out on the elution components with the petroleum ether/acetone volume ratio of 20/1; and carrying out gradient elution by using eluent with methanol/water volume ratio of 7/3, 8/2 and 9/1 in sequence through the reversed-phase RP-18 column chromatography, and collecting elution components with methanol/water volume ratio of 7/3.

Preferably, the precipitation purification in step c) means precipitation by standing at room temperature to obtain further purified cyclic lipopeptide compound H-1 (precipitation is caused by the small solubility of cyclic lipopeptide compound H-1 in methanol solution).

As a preferred preparation method, it comprises the following steps:

a) dried hong Kong

Extracting cortex Cinnamomi Japonici powder with 95% ethanol at room temperature for 3 times, evaporating to remove ethanol, and concentrating to obtain extract;

b) extracting and distributing the extract by using ethyl acetate and water, evaporating an organic solvent to dryness to obtain a crude extract, and sequentially carrying out gradient elution on the crude extract on a D101 macroporous adsorption resin column by using ethanol water solutions with volume fractions of 30%, 50%, 80% and 90% to respectively and correspondingly obtain four elution components F1, F2, F3 and F4;

c) and purifying and separating the eluted component F3 by MCI column chromatography, silica gel column chromatography and reversed-phase RP-18 column chromatography in sequence, and finally obtaining the cyclic lipopeptide compound H-1 by precipitation and purification.

The invention also provides a pharmaceutical composition comprising the cyclic lipopeptide compound H-1.

When the cyclic lipopeptide compound H-1 is used together with chemotherapeutic drugs, the tumor inhibition activity can be obviously improved.

The fourth technical problem to be solved by the invention is to provide the application of the cyclic lipopeptide compound H-1 or the pharmaceutical composition in preparing a medicament for treating multidrug resistant tumors.

Preferably, the medicine for treating the multidrug resistant tumor is used for improving the tumor inhibition activity when being used together with a chemotherapeutic medicine, and has a remarkable effect.

Preferably, the chemotherapeutic agent comprises one or more of vincristine, paclitaxel, and doxorubicin.

In the proliferation reaction biological experiments of P-gp high-expression multidrug-resistant tumor cells KBV200, MDR/ADR and K562/ADR, the novel skeleton cyclic lipopeptide compound H-1 is found to be used with chemotherapeutic drugs vincristine, paclitaxel and adriamycin respectively for the first time to obviously improve the tumor inhibition activity, when the concentration is 10 mu M, the synergistic multiple is between 28.4 and 1039.7 (the specific activity data is shown in table 1), and the compound has no obvious inhibition activity on the tumor cell proliferation when being used alone. The compound is a monomer compound which is found in natural products and has the effect of remarkably reversing the activity of multidrug-resistant tumor cells, and the compound is taken as an example to provide a basis for the development and structural modification of the skeleton compounds in the future.

Based on the advantages of the compound in the aspects of novel chemical structure, remarkable biological activity and the like, the compound has good development prospect and is expected to be developed into a medicament with novel structure for treating certain multidrug resistant tumors.

Detailed Description

The preparation steps and pharmacological experimental procedures of the compounds of the present invention are further illustrated by the following specific examples. It is to be understood that the following examples are illustrative only and are not intended to limit the scope of the invention, which is to be given all changes and modifications that may be suggested to persons skilled in the art without departing from the spirit and scope of the invention as defined in the appended claims.